Trials / Withdrawn
WithdrawnNCT04479904
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
A Single-Arm, Open-Label, Multi-Center, Phase II Study of Famitinib Malate to Treat Intrahepatic Cholangiocarcinoma Patients With FGFR2(Fibroblast Growth Factor Receptor2) Genetic Aberrations Who Failed First-Line Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic aberrations who failed first-line therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | po |
Timeline
- Start date
- 2020-08-10
- Primary completion
- 2021-12-10
- Completion
- 2022-02-10
- First posted
- 2020-07-21
- Last updated
- 2021-06-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04479904. Inclusion in this directory is not an endorsement.